Anticoagulation for people receiving long-term haemodialysis.
Patrizia Natale, Suetonia C Palmer, Marinella Ruospo...
https://pubmed.ncbi.nlm.nih.gov/38189593/Actively Recruiting
Led by Region Stockholm · Updated on 2024-10-04
1400
Participants Needed
34
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of apixaban as a stroke prevention treatment in adults with stage 5 chronic kidney disease CKD who also have atrial fibrillation AF or atrial flutter AFL. This study compares apixaban to no anticoagulation to see if it reduces the risk of ischemic stroke without increasing fatal or brain bleeding events. The trial also examines all-cause mortality, cardiovascular events, and major bleeding risks in this patient group. Participants are randomly assigned to one of two groups one receiving apixaban 2.5 mg twice daily plus standard care, and the other receiving standard care without anticoagulation. The study is open-label and conducted over 12 to 72 months across around 50 sites in several European countries. Patients already on warfarin, apixaban, or low molecular weight heparin may join after stopping their current anticoagulation. Routine blood tests are done at inclusion. During the trial, participants will be monitored for ischemic stroke, intracranial or fatal bleeding, death, cardiovascular events, and major bleeding according to established criteria. Additional outcomes include thromboembolic events and kidney transplant-related complications. The study lasts up to 72 months per participant or until a set number of events occur. Safety and efficacy data are reviewed by independent boards throughout the study.
CONDITIONS
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
M
Marie Evans, Ass Prof
C
Caroline Moberg
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Stockholm
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 72 months
Participants receive either apixaban 2.5 mg twice daily along with standard care or standard care without anticoagulation to prevent stroke.
Regular visits for prescription renewal and safety assessments as per local investigator schedule
Duration - Up to 72 months
Participants are monitored for efficacy and safety outcomes including stroke prevention and bleeding events after treatment.
Visits coincide with treatment period and end-of-study assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Patrizia Natale, Suetonia C Palmer, Marinella Ruospo...
https://pubmed.ncbi.nlm.nih.gov/38189593/Region Stockholm
Lead Sponsor